Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,662,510
  • Shares Outstanding, K 142,609
  • Annual Sales, $ 330,530 K
  • Annual Income, $ -145,220 K
  • 60-Month Beta 1.39
  • Price/Sales 8.15
  • Price/Cash Flow N/A
  • Price/Book 2.27
Trade DNLI with:

Options Overview Details

View History
  • Implied Volatility 81.21% ( +4.57%)
  • Historical Volatility 55.79%
  • IV Percentile 95%
  • IV Rank 72.18%
  • IV High 96.66% on 05/01/24
  • IV Low 41.13% on 09/27/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 75
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 3,715
  • Open Int (30-Day) 3,805

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.68
  • Number of Estimates 10
  • High Estimate -0.54
  • Low Estimate -0.84
  • Prior Year 1.30
  • Growth Rate Est. (year over year) -152.31%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.56 +27.61%
on 04/25/24
20.25 -8.25%
on 05/08/24
+0.16 (+0.87%)
since 04/10/24
3-Month
14.56 +27.61%
on 04/25/24
23.52 -21.00%
on 02/27/24
+0.53 (+2.94%)
since 02/09/24
52-Week
14.56 +27.61%
on 04/25/24
33.31 -44.22%
on 06/16/23
-9.79 (-34.51%)
since 05/10/23

Most Recent Stories

More News
Flagship Pioneering Announces the Merger of Two Leading Programmable Medicine Platforms to Form Sail Biomedicines

/PRNewswire/ -- Flagship Pioneering today announced the combination of Laronde and Senda Biosciences to launch Sail Biomedicines, a company pioneering the...

DNLI : 18.68 (+0.05%)
FHTX : 5.81 (-2.27%)
MRNA : 119.15 (-2.89%)
OMGA : 2.00 (-7.83%)
SANA : 7.81 (+4.13%)
MCRB : 1.0100 (-1.94%)
Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFoundâ„¢ Therapeutics, a company pioneering the discovery of a vastly expanded...

DNLI : 18.68 (+0.05%)
FHTX : 5.81 (-2.27%)
MRNA : 119.15 (-2.89%)
OMGA : 2.00 (-7.83%)
SANA : 7.81 (+4.13%)
MCRB : 1.0100 (-1.94%)
Flagship Pioneering Named to Fortune's 2023 "Change the World" List

/PRNewswire/ -- Flagship Pioneering today announced it has been named to FORTUNE's 2023 "Change the World" list, an annual global ranking of companies that...

DNLI : 18.68 (+0.05%)
FHTX : 5.81 (-2.27%)
MRNA : 119.15 (-2.89%)
OMGA : 2.00 (-7.83%)
SANA : 7.81 (+4.13%)
MCRB : 1.0100 (-1.94%)
Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today the appointment of Amanda Kay as Senior Partner and Chief Business...

DNLI : 18.68 (+0.05%)
FHTX : 5.81 (-2.27%)
MRNA : 119.15 (-2.89%)
OMGA : 2.00 (-7.83%)
SANA : 7.81 (+4.13%)
MCRB : 1.0100 (-1.94%)
Flagship Pioneering Announces Appointment of David Khougazian as Growth Partner

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, announced today that pharma and healthcare leader David Khougazian is joining as...

DNLI : 18.68 (+0.05%)
FHTX : 5.81 (-2.27%)
MRNA : 119.15 (-2.89%)
OMGA : 2.00 (-7.83%)
SANA : 7.81 (+4.13%)
MCRB : 1.0100 (-1.94%)
Flagship Pioneering Appoints Jason Gardner as CEO-Partner and CEO of Ampersand Biomedicines

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Ampersand Biomedicines, a company programming smarter medicines that act...

DNLI : 18.68 (+0.05%)
FHTX : 5.81 (-2.27%)
MRNA : 119.15 (-2.89%)
OMGA : 2.00 (-7.83%)
SANA : 7.81 (+4.13%)
MCRB : 1.0100 (-1.94%)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

DNLI : 18.68 (+0.05%)
RARE : 40.70 (-1.26%)
SRPT : 129.84 (-1.86%)
PFE : 28.00 (-0.64%)
EXEL : 21.67 (-0.41%)
MRNA : 119.15 (-2.89%)
UTHR : 266.59 (+0.20%)
BIIB : 222.22 (-0.24%)
SNY : 49.08 (+0.80%)
LLY : 767.10 (-0.58%)
Why Shares of Denali Therapeutics Are Up Monday

Analysts maintained their buy ratings on the clinical-stage biotech company.

DNLI : 18.68 (+0.05%)
Denali (DNLI) Q1 Earnings Miss Estimates, Pipeline in Focus

Denali (DNLI) delivers a wider Q1 loss while collaboration revenues surpass estimates.

SNY : 49.08 (+0.80%)
BIIB : 222.22 (-0.24%)
LGND : 86.49 (+0.43%)
DNLI : 18.68 (+0.05%)
Denali Therapeutics Inc. (DNLI) Reports Q1 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -12.68% and 15.13%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 18.68 (+0.05%)
SQZ : 0.4350 (+61.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program...

See More

Key Turning Points

3rd Resistance Point 19.87
2nd Resistance Point 19.52
1st Resistance Point 19.09
Last Price 18.68
1st Support Level 18.32
2nd Support Level 17.97
3rd Support Level 17.54

See More

52-Week High 33.31
Fibonacci 61.8% 26.15
Fibonacci 50% 23.94
Fibonacci 38.2% 21.72
Last Price 18.68
52-Week Low 14.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar